Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.13 USD | +9.88% | +4.13% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 375M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials